Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: A French Cancer Centre multicentric study

European Journal of Cancer

Volumn 32, Issue 3, 1996, Pages 455-460

  Iliadis, A ^a   Launay Iliadis, M C ^a   Lucas, C ^b   Fety, R ^c   Lokiec, F ^d   Tranchand, B ^e   Milano, G ^f  

^a AIX MARSEILLE UNIVERSITY   (France)

^b IRIS Institut de Recherches Internationales Servier   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d CENTRE RENÉ HUGUENIN   (France)

^e CENTRE LÉON BÉRARD   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Dose dependence; Fotemustine; Modelling toxicity; Pharmacodynamics; Pharmacokinetics; Time dependence

Indexed keywords

FOTEMUSTINE;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0029994657     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00565-X     Document Type: Article

References (30)

1. Foster DO, Pardee AB. Transport of amino-acids by confluent and non confluent 3T3 and polyoma virus transformed 3T3 cells growing on glass cover slips. J Biol Chem 1969, 244, 2675-2681.
2. Montgomery JA, Mayo JG, Hansch C. Quantitative structure-activity relationship of anticancer agents. Activity of selected nitrosoureas against a solid tumor: the Lewis lung carcinoma. J Med Chem 1974, 17, 477-480.
3. Tapiero H, Ming-Biao Y, Catalin J, et al. Cytotoxicity in DNA damaging effects of a new nitrosourea, fotemustine, diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S 10036. Anticancer Res 1989, 9, 1617-1622.
4. Fischel JL, Formento P, Etienne MC, et al. In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 1990, 25, 337-341.
5. Khayat D, Lokiec F, Bizzari JP, et al. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987, 47, 6782-6785.
6. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicentre phase II study of die nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasis. Cancer 1990, 66, 1873-1878.
7. Avril MF, Bonneterre J, Delaunay M, et al. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Cancer Chemother Pharmacol 1990, 27, 81-84.
8. Frenay M, Giroux B, Khoury S, Derlon JM, Namer M. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 1991, 27, 852-856.
9. McDonald JS, Weiss RB, Poster D, Hammershaim B. Subacute and chronic toxicities associated with nitrosoureas therapy. In Prestayko AM, Crooke ST, Baker LH, et al., eds. Nitrosureas: Current Status and New Developments. New York, Academic Press, 1981, 145-154.
10. 14C-fotemustine in cancer patients. Eur J Cancer 1990, 26, 838-842.
11. Ratain MJ, Schilsky RL, Coney BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990, 8, 1739-1753.
12. Newell DR. Pharmacokinetic determinants of the activity and toxicity of antitumor agents. Cancer Surveys 1989, 8, 557-603.
13. Thyss A, Milano G, Renée N, Vallicioni J, Schneider M, Demard F. Clinical pharmacokinetic study of 5FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986, 16, 64-66.
14. Santini J, Milano G, Thyss A, et al. 5FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989, 59, 287-290.
15. Egorin MJ, VanEcho DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutane dicarboxylate) platinum in patients with impaired renal function. Cancer Res 1984, 44, 5432-5438.
16. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1756.
17. Gordon BH, Richards RP, Hiley MP, Gray AJ, Ings RMJ, Campbell DB. A new method for the treatment of nitrosoureas in plasma: an HPLC procedure for the measurement of fotemusrine kinetics. Xenobiotica 1989, 19, 329-339.
18. Ilidis A, Brown AC, Huggins ML. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Meth Prog Biomed 1992, 38, 227-239.
19. Astrom KJ, Eykhoff P. System identification: a survey. Automatica 1971, 7, 123-162.
20. Dixon WJ, Brown MB, Engelman L, et al. BMDP Statistical Software, University of California Press, 1985.
21. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989, 16, 327-336.
22. Liliemark J, Peterson C. Pharmacokinetic optimisation of anticancer therapy. Clin Pharmacokinet 1991, 21, 213-231.
23. Levin VA, Hoffman W, Weinkam RJ. Pharmacokinetics of BCNU in man, a preliminary study of 20 patients. Cancer Treat Rep 1978, 62, 1305-1312.
24. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I trials based upon preclinical drug development. J Natl Cancer Inst 1990, 82, 1321-1326.
25. EORTC Pharmacokinetics and Metabolism Group. Pharmacokinetically guided dose escalation in phase I clinical trials. Eur J Cancer Clin Oncol 1987, 23, 1083-1087.
26. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles of preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986, 70, 73-79.
27. Lucas C, Ings RMJ, Gray AJ, et al. Interspecies comparison of pharmacokinetic parameters of fotemustine (nitrosourea S 10036): mice, rats, monkeys, dogs and man. Bull Cancer 1989, 76, 863-865.
28. DeJong J, Geijssen GJ, Munniksma CN, Vermorken JB, Van Der Vijgh WJF. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-1-leucyldoxorubicin and its metabolites in a phase I clinical trial. J Clin Oncol 1992, 10, 1897-1906.
29. Weiss RB, Isbel BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 1982, 9, 313-330.
30. Sheiner LB, Beal SL, Rosenberg B, Marathe W. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979, 26, 294-305.